GlassScriptPhysician profile
Lucy Alberda
NPI 1629780879
$1,508.61
in general payments reported to CMS, 2019-2025
19 companies · $28.53 in 2025
The $28.53 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,167 · 2024: $313 · 2025: $28.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,508.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $272.39 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $260.63 | 2023-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $149.47 | 2023-2024 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $122.12 | 2023 | |
| Novo Nordisk INC | $87.85 | 2023-2024 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $80.17 | 2023-2024 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $66.10 | 2023 | Rexulti |
| Astellas Pharma US INC | $65.04 | 2023-2024 | Veozah, Myrbetriq |
| Amgen INC. | $62.80 | 2023-2024 | Evenity, Prolia |
| Axsome Therapeutics, INC. | $52.80 | 2023 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.53 | 2023 | Jardiance, Tradjenta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.66 | 2023-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $40.30 | 2023 | Trintellix |
| Corium, LLC | $33.45 | 2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $32.02 | 2023 | Quviviq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.23 | 2023-2024 | |
| Boston Scientific Corporation | $28.53 | 2025 | General - Thrombectomy |
| Merck Sharp & Dohme LLC | $19.39 | 2023 | Verquvo, Belsomra, Steglatro |
| Ironshore Pharmaceuticals INC. | $13.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Alberda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.